Company Overview: Abiologics, Inc. is a privately held, early-stage biotechnology company on a mission to make biology better through chemistry. We are pioneering the development of SynteinsTM, a transformational class of macromolecular medicines unlocked by novel synthetic and computational technologies. Abiologics is actively seeking exceptional molecular scientists who are passionate about driving chemical innovation in biotechnology.
Abiologics was founded in Flagship Pioneering’s venture creation engine, where companies such as Moderna Therapeutics (NASDAQ: MRNA) and Generate Biomedicines were conceived and created. Since Flagship’s founding in 2000, the firm has originated and fostered the development of more than 100 scientific ventures resulting in more than 500 issued patents and more than 50 clinical trials for novel therapeutic agents.
Position Summary: As part of the Abiologics team, Principal Machine Learning Researchers are responsible for developing the frameworks and core models that drive advancements in our drug discovery process. Successful candidates will collaborate closely with expert protein designers, the software infrastructure team, and members of the experimental team to create impactful models that enhance our drug discovery pipelines.
Responsibilities:
- Design and conduct independent machine learning research, driven by our team’s scientific milestones.
- Collaborate closely with experimental teams to align with their capabilities, enabling the creation of advanced hybrid platforms.
- Deliver production-quality models which will power our next way of drug discovery.
Qualifications:
- A PhD in biophysics, computational chemistry, computer science, AI/ML, or a related discipline solving biological or chemical problems using computational approaches.
- Demonstrated experience with computational approaches to the modeling, simulation, and design of biomolecules (proteins, peptides, DNA/RNA, small molecules, etc.).
- Demonstrated experience in the Python programming language in addition to standard machine learning tools (PyTorch, PyG, PyMC, etc).
Preferred:
- 5+ years of industry experience in machine learning.
- Excellent collaboration skills, with the ability to think independently and contribute to a dynamic intellectual environment.
- Expertise with common software development tools and best practices: Git, cloud/cluster computing, testing frameworks, etc.
- A history of managing machine learning projects with multiple team members.
- Experience with workflow tools such as Dask, Prefect, MLFlow, etc
- Experience with a variety of deep learning models (such as GNNs, diffusion models, large language models, etc.)
- Experience developing novel AI, structure, or sequence-based methods for biomolecular design.
- Experience working on complex scientific problems within a collaborative group setting
At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.
About Flagship Pioneering:
Flagship Pioneering is a bioplatform innovation company that invents and builds platform companies that change the world. We bring together the greatest scientific minds with entrepreneurial company builders and assemble the capital to allow them to take courageous leaps. Those big leaps in human health and sustainability exponentially accelerate scientific progress in areas ranging from cancer detection and treatment to nature-positive agriculture. What sets Flagship apart is our ability to advance biotechnology by uniting life science innovation, company creation, and capital investment under one roof in a way that is largely without precedent. Our scientific founders, entrepreneurial leaders, and professional capital managers are each aligned around an institutionalized process that enables us to innovate and transform for the benefit of people and planet. Many of the companies Flagship has founded have addressed humanity’s most urgent challenges: vaccinating billions of people against COVID-19, curing intractable diseases, improving human health, preempting illness, and feeding the world by improving the resiliency and sustainability of agriculture.
Flagship has been recognized twice on FORTUNE’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies, and has been twice named to Fast Company’s annual list of the World’s Most Innovative Companies.
Flagship Pioneering and our ecosystem companies are committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
Recruitment & Staffing Agencies: Flagship Pioneering and its affiliated Flagship Lab companies (collectively, “FSP”) do not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to FSP or its employees is strictly prohibited unless contacted directly by Flagship Pioneering’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of FSP, and FSP will not owe any referral or other fees with respect thereto.
Top Skills
What We Do
Flagship Pioneering conceives, creates, resources, and develops first-in-category life sciences companies to transform human health and sustainability.
Since its launch in 2000, the firm has applied a unique, hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $30 billion in aggregate value. To date, Flagship is backed by >$3 billion of aggregate capital commitments, of which over $1.5 billion has been deployed toward the founding and growth of its pioneering companies alongside >$10 billion of follow-on investments from other institutions.
The current Flagship ecosystem includes Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Moderna Therapeutics (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Seres Therapeutics (NASDAQ: MCRB), and Syros Pharmaceuticals (NASDAQ: SYRS).
